Cargando…
pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea
BACKGROUND: Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH. The purpose of this study was to compare PZA resistance with pyrazinamidase (PZase) activity and the genotype to better understand the molecular...
Autores principales: | Park, Soon Kew, Lee, Jung Yoo, Chang, Chulhun Ludgerus, Lee, Min Ki, Son, Han Chul, Kim, Cheol Min, Jang, Hyun Jung, Park, Hee Kyung, Jeong, Seok Hoon |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC33507/ https://www.ncbi.nlm.nih.gov/pubmed/11429043 http://dx.doi.org/10.1186/1471-2334-1-4 |
Ejemplares similares
-
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
por: Lee, K. W., et al.
Publicado: (2001) -
pncA Mutations in the Specimens from Extrapulmonary Tuberculosis
por: Lee, Jaechun, et al.
Publicado: (2012) -
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
por: Shi, Dawei, et al.
Publicado: (2022) -
Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan
por: Chiu, Yu-Chi, et al.
Publicado: (2011) -
pncA Large Deletion is the Characteristic of Pyrazinamide-Resistant Mycobacterium tuberculosis belonging to the East Asian Lineage
por: Kim, Na Yung, et al.
Publicado: (2023)